Get started
Work

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

Year: 2013
Type: article
Study design: Clinical Trial
DOI: 10.1007/s00280-013-2297-4
Authors: Shirish M. Gadgeel, Danika L. Lew, Timothy W. Synold, Patricia LoRusso, Vincent Chung, Scott D. Christensen, David C. Smith, Laura Kingsbury, Antje Hoering, Razelle Kurzrock
Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, SWOG Cancer Research Network, City Of Hope National Medical Center, City of Hope, University of California, Davis, University of Michigan, University of California San Diego, Moores Cancer Center
Language: English
Open Access status: green
Awards: SOUTHWEST ONCOLOGY GROUP, G1545560008, G1548551769, G1958973285, G1985252453, G2043432835, G2435896781, G2485941414, G268786457, SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER, UCDCCC NCTN U10 Program, G3337849518, City of Hope Southwest Oncology Group Clinical Trials, G3647597407, G36541222, G379387698, G425646771, Southwest Oncology Group, G444114835, G4527800867, G5566132837, G591690631, G6782300252, G7520596819, G772794905, G8898045420, CANCER CENTER SUPPORT GRANT
OpenAlex ID: W2017562064
FWCI: 1.21
Cites: 27
Cited by: 25
Related to: 10